Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2018, Article ID 8954718, 5 pages
https://doi.org/10.1155/2018/8954718
Research Article

Serum Presepsin Levels Are Not Elevated in Patients with Controlled Hypertension

1Department of Cardiology, School of Medicine, Education and Research Hospital, Uşak University, Uşak, Turkey
2Department of Cardiology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
3Department of Biochemistry, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
4Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey

Correspondence should be addressed to Ismail Biyik; moc.oohay@dmkiyibliamsi

Received 6 November 2017; Revised 3 January 2018; Accepted 11 January 2018; Published 8 February 2018

Academic Editor: Tomohiro Katsuya

Copyright © 2018 Ismail Biyik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Hypertension: uncontrolled and conquering the world,” The Lancet, vol. 370, no. 9587, p. 539, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Savoia and E. L. Schiffrin, “Inflammation in hypertension,” Current Opinion in Nephrology and Hypertension, vol. 15, no. 2, pp. 152–158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Tsounis, G. Bouras, G. Giannopoulos, C. Papadimitriou, D. Alexopoulos, and S. Deftereos, “Inflammation markers in essential hypertension,” Medicinal Chemistry, vol. 10, no. 7, pp. 672–681, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Virdis, U. Dell'agnello, and S. Taddei, “Impact of inflammation on vascular disease in hypertension,” Maturitas, vol. 78, no. 3, pp. 179–183, 2014. View at Publisher · View at Google Scholar
  5. H. Ishikura, T. Nishida, A. Murai et al., “New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: A prospective single-center observational study,” Critical Care, vol. 18, no. 1, article no. R19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Behnes, T. Bertsch, D. Lepiorz et al., “Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment,” Critical Care, vol. 18, no. 5, article no. 507, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Ovayolu, Ö. Özdamar, İ. Gün et al., “Can blood or follicular fluid levels of presepsin predict reproductive outcomes in ART; A preliminary study,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 5, pp. 7983–7988, 2015. View at Google Scholar · View at Scopus
  8. F. N. Caglar, N. Isiksacan, I. Biyik, S. Opan, H. Cebe, and I. F. Akturk, “Presepsin (sCD14-ST): could it be a novel marker for the diagnosis of ST elevation myocardial infarction?” Archives of Medical Science - Atherosclerotic Diseases, vol. 2, pp. 3–8, 2017. View at Publisher · View at Google Scholar
  9. G. Mancia, R. Fagard, and K. Narkiewicz, “2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC),” European Heart Journal, vol. 34, pp. 2159–2219, 2013. View at Publisher · View at Google Scholar
  10. E. Olad, I. Sedighi, A. Mehrvar et al., “Presepsin (Scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia,” Iranian Journal of Pediatrics, vol. 24, no. 6, pp. 715–722, 2014. View at Google Scholar · View at Scopus
  11. T. Nagata, Y. Yasuda, M. Ando et al., “Clinical impact of kidney function on presepsin levels,” PLoS ONE, vol. 10, no. 6, Article ID e0129159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Giavarina and M. Carta, “Determination of reference interval for presepsin, an early marker for sepsis,” Biochemia Medica, vol. 25, no. 1, pp. 64–68, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. Zheng, L. Jiang, L. Ye, Y. Gao, L. Tang, and M. Zhang, “The accuracy of presepsin for the diagnosis of sepsis from SIRS: a systematic review and meta-analysis,” Annals of Intensive Care, vol. 5, no. 1, article no. 48, pp. 1–13, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. S. Hou, H. Wang, H. Chen, L. F. Wu, L. F. Lu, and Y. He, “Pathfast presepsin assay for early diagnosis of systemic inflammatory response syndrome in patients with nephrolithiasis,” BioMed Research International, vol. 2015, Article ID 792572, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Endo, Y. Suzuki, G. Takahashi et al., “Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study,” Journal of Infection and Chemotherapy, vol. 18, no. 6, pp. 891–897, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Popov, M. Plyushch, S. Ovseenko, M. Abramyan, O. Podshchekoldina, and M. Yaroustovsky, “Prognostic value of sCD14-ST (presepsin) in cardiac surgery,” Kardiochirurgia i Torakochirurgia Polska, vol. 12, no. 1, pp. 30–36, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Shozushima, G. Takahashi, N. Matsumoto, M. Kojika, Y. Okamura, and S. Endo, “Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome,” Journal of Infection and Chemotherapy, vol. 17, no. 6, pp. 764–769, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Klouche, J. P. Cristol, J. Devin et al., “Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients,” Annals of Intensive Care, vol. 6, no. 1, article no. 59, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Masson, P. Caironi, and E. Spanuth, “Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial,” Critical Care, vol. 18, no. 1, article R6, 2014. View at Publisher · View at Google Scholar
  20. C. Chenevier-Gobeaux, E. Trabattoni, M. Roelens, D. Borderie, and Y.-E. Claessens, “Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values?” Clinica Chimica Acta, vol. 427, pp. 34–36, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Bomberg, M. Klingele, S. Wagenpfeil et al., “Presepsin (sCD14-ST) Is a Novel Marker for Risk Stratification in Cardiac Surgery Patients,” Anesthesiology, vol. 126, no. 4, pp. 631–642, 2017. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Khaksari, SE. Mahani, and M. Mahmoodi, “Calcium channel blockers reduce inflammatory edema in the rat,” Indian Journal Pharmacology, vol. 36, pp. 335–351, 2004. View at Google Scholar
  23. T. Ohtsuka, M. Hamada, G. Hiasa et al., “Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy,” Journal of the American College of Cardiology, vol. 37, no. 2, pp. 412–417, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Di Raimondo, A. Tuttolomondo, C. Buttà, S. Miceli, G. Licata, and A. Pinto, “Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation,” Current Pharmaceutical Design, vol. 18, no. 28, pp. 4385–4413, 2012. View at Publisher · View at Google Scholar · View at Scopus